Incyte Corporation

Incyte Corporation

INCYNYSE / NASDAQHealthcareLarge cap

$114.63-$1.24 (-1.1%)

Last close · Data as of Nov 20, 2026

Market cap
$20.2B
P/E
15.7x
EV / EBITDA
9.8x
Revenue
$5.1B
Net margin
25.0%
ROCE
24.7%

+12.6% over the last year

Incyte Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-1.7%
3M
-9.9%
6M
+18.1%
1Y
+12.6%
5Y
+77.7%

52-week range

Day change -$1.24 (-1.1%) from $116 to $115 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in INCY, bought on each weekday since 2021.

News & filings

What Incyte filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating profit was more than a hundred times interest costs.

Concerns

No concern stands out for this company on the data on file.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.

Read moreShow less

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Sector
Healthcare
Shares outstanding
195.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$20.2B
P/E
15.7x
P/B
3.9x
EV / EBITDA
9.8x
EV / Sales
3.3x
P/S
3.9x
52-week high
$129.93
52-week low
$90.30

Profitability

Operating margin
26.1%
Net margin
25.0%
EBITDA margin
34.2%
ROE
24.9%
ROCE
24.7%
ROA
18.5%
Asset turnover
0.74

Growth

Revenue
$5.1B
Revenue growth, 1Y
21.2%
Revenue CAGR, 3Y
14.8%
Net profit growth, 1Y
3845.0%
Free cash flow
$1.3B

Solvency

Current ratio
3.32
Debt / Equity
0.01
Debt / Assets
0.01
CFO / Net profit
1.10
Cash / Market cap
15.3%

Where the revenue went

Of every $100 of FY2025 revenue, $25 was left as net income.

Incyte Corporation income statement flow, FY2025
Incyte Corporation income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$372.1M
RevenueGross profit$4.8B
Gross profitOperating expenses$3.4B
Gross profitOperating income$1.3B
Operating incomePretax income$1.3B
Interest and other incomePretax income$321.7M
Pretax incomeTax and other$377.8M
Pretax incomeNet income$1.3B

Revenue and net profit

Revenue grew 21.2% in FY2025; net profit is the dashed line.

Incyte Corporation revenue and net profit by fiscal year
Incyte Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$3.4B$340.7M
FY2023$3.7B$597.6M
FY2024$4.2B$32.6M
FY2025$5.1B$1.3B

Cash flows

FY2025: $1.4B from operations, $1.3B free after investment (dashed).

Incyte Corporation operating and free cash flow by fiscal year
Incyte Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$969.9M$892.1M
FY2023$496.5M$449.0M
FY2024$335.3M$235.2M
FY2025$1.4B$1.3B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$5.1B+21.2%1Y
EBITDA
$1.8B+331.2%1Y
Net profit
$1.3B+3,845.0%1Y
Cash from operations
$1.4B+321.5%1Y
Free cash flow
$1.3B+465.4%1Y
Revenue CAGR, 3Y
14.8%
Net profit CAGR, 3Y
55.7%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$5.1B$1.8B$1.3B$1.3B24.9%+21.2%+3845.0%

Monthly returns

Month-by-month returns of INCY across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$7.0B
Liabilities$1.8B
Equity$5.2B
Paid-in capital$4.9B
Retained earnings$213.8M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; INCY highlighted.

P/E against peers

INCY trades at 15.7x earnings against a peer median of 23.8x (a 34% discount).

Not shown (no positive earnings and no EV / Sales): Insmed Incorporated, Moderna, Inc., Viatris Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Incyte CorporationINCYthis companyP/E ↓ discount$20.2B15.7x3.9x24.9%9.8x
Insmed IncorporatedINSM$22.7B-17.8x30.8x-172.8%—
West Pharmaceutical Services, Inc.WST$22.4B45.4x7.1x15.5%28.4x
Quest Diagnostics IncorporatedDGX$21.7B21.9x3.0x13.8%12.9x
Labcorp Holdings Inc.LH$21.4B24.4x2.5x10.2%13.6x
STERIS plcSTE$20.7B26.5x2.9x10.9%14.0x
Moderna, Inc.MRNA$20.5B-7.3x2.4x-32.6%-7.5x
Viatris Inc.VTRS$18.5B—1.3x-23.9%—
Zimmer Biomet Holdings, Inc.ZBH$16.8B23.8x1.3x5.6%10.7x
Peer median—23.8x2.7x7.9%13.2x

Year-to-date ROI

INCY since 1 January, against earlier years.

Historical volatility

INCY's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Incyte Corporation operating margin by fiscal year
Incyte Corporation operating margin by fiscal year
DateOperating margin
FY202217.4%
FY202317.7%
FY20242.4%
FY202526.1%
LineFY2025
Cost of revenueCost Of Revenue$372.1M
Gross profitGross Profit$4.8B
Operating expensesOperating Expense$3.4B
Research and developmentResearch And Development$2.1B
Other operating expensesOther Operating Expenses—
Total expensesTotal Expenses$3.8B
Pretax incomePretax Income$1.7B

Learn while you research

Academy chapters picked for Incyte Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing21% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →